| abstract |
Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as a Nuclear Factor-kB (NF-kB) inhibitor formula (I), wherein: A has the following structure; formula (i) Z is -COOH5 -P(O)(OH)2 or -SO2OH ; each R1 is the same or different and is halogen, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkylthio, thio, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano or -CO2R/, wherein R/ represents hydrogen or C1-6 alkyl; n is 0, 1, 2 or 3; R2 is hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; Y is a linking group; and X is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -M-aryl, -M-heteroaryl, -M-carbocyclyl or -M-heterocyclyl, wherein M is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, -Q-Het-Q'- or -Q-Het- wherein Q and Q' are the same or different and are C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene and Het is selected from -NR/-, -O-, -S-, -SO2-, -SO-, -C(O)-O-, -OC(O), -CO-, -C(O)-NR/- or -NR/-C(O)- wherein R/ is as defined above, provided that: when n is 0, Z is -COOH, R2 is hydrogen and Y is -N=N-, X is other than 2-pyridyl. |